Neurogene Inc. also files under NGNE, AQXP; those filings are included. Filings under NLTX by Nile Therapeutics, Inc. (CIK 0001133869) from Mar 10, 2008 to Mar 30, 2012 belong to a different issuer and are not shown.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 7, 2026 | Cvijic Christine Mikail | President and CFO, Director | Sell(S) | 4K | $36.13 | $152K |
| Jul 6, 2026 | Cvijic Christine Mikail | President and CFO, Director | Sell(S) | 600 | $36.02 | $22K |
| Jul 2, 2026 | Cvijic Christine Mikail | President and CFO, Director | Sell(S) | 3K | $34.58 | $88K |
| Jul 2, 2026 | Cvijic Christine Mikail | President and CFO, Director | Sell(S) | 2K | $35.23 | $54K |
| Jul 1, 2026 | Cvijic Christine Mikail | President and CFO, Director | Sell(S) | 739 | $34.06 | $25K |
| May 6, 2026 | Cvijic Christine Mikail | President and CFO, Director | Sell(S) | 5K | $32.44 | $156K |
| May 6, 2026 | Cvijic Christine Mikail | President and CFO, Director | Sell(S) | 5K | $30.07 | $144K |
| May 5, 2026 | Shafer Christina | Chief Commercial Officer | Grant(A) | 120K | — | $0 |
| Mar 26, 2026 | McMinn Rachel | Chief Executive Officer, Director | Sell(S) | 3K | $22.07 | $74K |
| Mar 26, 2026 | Cvijic Christine Mikail | President and CFO | Sell(S) | 3K | $21.62 | $55K |
| Mar 26, 2026 | Jordan Julie | Chief Medical Officer | Sell(S) | 828 | $21.89 | $18K |
| Mar 13, 2026 | Cvijic Christine Mikail | President and CFO | Sell(S) | 1K | $21.25 | $30K |
| Mar 13, 2026 | Cvijic Christine Mikail | President and CFO | Sell(S) | 263 | $22.02 | $6K |
| Mar 13, 2026 | Cobb Stuart | Chief Scientific Officer | Sell(S) | 148 | $22.08 | $3K |
| Mar 13, 2026 | Cobb Stuart | Chief Scientific Officer | Sell(S) | 4K | $20.41 | $81K |
| Mar 13, 2026 | Cobb Stuart | Chief Scientific Officer | Sell(S) | 3K | $21.34 | $57K |
| Mar 13, 2026 | Cvijic Christine Mikail | President and CFO | Sell(S) | 2K | $20.42 | $49K |
| Feb 27, 2026 | Cvijic Christine Mikail | President and CFO | Sell(S) | 5K | $25.11 | $121K |
| Feb 20, 2026 | Jordan Julie | Chief Medical Officer | Grant(A) | 5K | — | $0 |
| Feb 20, 2026 | Freedland Cory S. | Director | Grant(A) | 12K | — | $0 |
| Feb 20, 2026 | Noonberg Sarah B. | Director | Grant(A) | 12K | — | $0 |
| Feb 20, 2026 | Cvijic Christine Mikail | President and CFO | Grant(A) | 22K | — | $0 |
| Feb 20, 2026 | McMinn Rachel | Chief Executive Officer, Director | Grant(A) | 155K | — | $0 |
| Feb 20, 2026 | McMinn Rachel | Chief Executive Officer, Director | Grant(A) | 26K | — | $0 |
| Feb 20, 2026 | Woods Keith | Director | Grant(A) | 12K | — | $0 |
| Feb 20, 2026 | Baffi Robert | Director | Grant(A) | 12K | — | $0 |
| Feb 20, 2026 | Cobb Stuart | Chief Scientific Officer | Grant(A) | 17K | — | $0 |
| Feb 20, 2026 | Palekar Rohan | Director | Grant(A) | 12K | — | $0 |
| Feb 20, 2026 | Jordan Julie | Chief Medical Officer | Grant(A) | 30K | — | $0 |
| Feb 20, 2026 | Cvijic Christine Mikail | President and CFO | Grant(A) | 132K | — | $0 |
| Jun 12, 2025 | Noonberg Sarah B. | Director | Grant(A) | 12K | — | $0 |
| Jun 12, 2025 | Baffi Robert | Director | Grant(A) | 12K | — | $0 |
| Jun 12, 2025 | Woods Robert Keith | Director | Grant(A) | 12K | — | $0 |
| Jun 12, 2025 | Palekar Rohan | Director | Grant(A) | 12K | — | $0 |
| Jun 12, 2025 | Freedland Cory S. | Director | Grant(A) | 12K | — | $0 |
| Jun 12, 2025 | Woods Keith | Director | Grant(A) | 12K | — | $0 |
| May 14, 2025 | Cobb Stuart | Chief Scientific Officer | Sell(S) | 7K | $15.15 | $103K |
| Mar 26, 2025 | McMinn Rachel | Chief Executive Officer, Director | Grant(A) | 144K | — | $0 |
| Mar 26, 2025 | McMinn Rachel | Chief Executive Officer, Director | Grant(A) | 24K | — | $0 |
| Mar 26, 2025 | Cobb Stuart | Chief Scientific Officer | Grant(A) | 7K | — | $0 |
| Mar 26, 2025 | Jordan Julie | Chief Medical Officer | Grant(A) | 50K | — | $0 |
| Mar 26, 2025 | Cobb Stuart | Chief Scientific Officer | Grant(A) | 43K | — | $0 |
| Mar 26, 2025 | Jordan Julie | Chief Medical Officer | Grant(A) | 8K | — | $0 |
| Mar 26, 2025 | Cvijic Christine Mikail | President and CFO | Grant(A) | 122K | — | $0 |
| Mar 26, 2025 | Cvijic Christine Mikail | President and CFO | Grant(A) | 20K | — | $0 |
| Mar 13, 2025 | Cvijic Christine Mikail | President and CFO | Sell(S) | 5K | $16.94 | $76K |
| Nov 26, 2024 | Akkaraju Srinivas | 10% Owner | Buy(P) | 2K | $27.50 | $55K |
| Nov 26, 2024 | Akkaraju Srinivas | 10% Owner | Buy(P) | 21K | $24.91 | $517K |
| Nov 26, 2024 | Akkaraju Srinivas | 10% Owner | Buy(P) | 11K | $26.01 | $281K |
| Nov 26, 2024 | Akkaraju Srinivas | 10% Owner | Buy(P) | 15K | $26.73 | $407K |
| Nov 22, 2024 | Cvijic Christine Mikail | President and CFO | Buy(P) | 24K | $20.48 | $492K |
| Nov 22, 2024 | McMinn Rachel | Chief Executive Officer, Director | Buy(P) | 48K | $20.40 | $969K |
| Jun 14, 2024 | Noonberg Sarah B. | Director | Grant(A) | 8K | — | $0 |
| Jun 14, 2024 | Baffi Robert | Director | Grant(A) | 8K | — | $0 |
| Jun 14, 2024 | Woods Robert Keith | Director | Grant(A) | 8K | — | $0 |
| Jun 14, 2024 | Palekar Rohan | Director | Grant(A) | 8K | — | $0 |
| Jun 14, 2024 | Freedland Cory S. | Director | Grant(A) | 8K | — | $0 |
| Jun 14, 2024 | Woods Keith | Director | Grant(A) | 8K | — | $0 |
| Mar 13, 2024 | McMinn Rachel | Chief Executive Officer, Director | Grant(A) | 93K | — | $0 |
| Mar 13, 2024 | Cvijic Christine Mikail | President and CFO | Grant(A) | 32K | — | $0 |
| Mar 13, 2024 | Cvijic Christine Mikail | President and CFO | Grant(A) | 54K | — | $0 |
| Mar 13, 2024 | Cobb Stuart | Chief Scientific Officer | Grant(A) | 34K | — | $0 |
| Mar 13, 2024 | Cobb Stuart | Chief Scientific Officer | Grant(A) | 20K | — | $0 |
| Jan 16, 2024 | Palekar Rohan | Director | Grant(A) | 15K | — | $0 |
| Jan 16, 2024 | Woods Robert Keith | Director | Grant(A) | 15K | — | $0 |
| Jan 16, 2024 | Jordan Julie | Chief Medical Officer | Grant(A) | 75K | — | $0 |
| Jan 16, 2024 | Noonberg Sarah B. | Director | Grant(A) | 15K | — | $0 |
| Jan 16, 2024 | Freedland Cory S. | Director | Grant(A) | 15K | — | $0 |
| Jan 16, 2024 | Baffi Robert | Director | Grant(A) | 15K | — | $0 |
| Jan 16, 2024 | Woods Keith | Director | Grant(A) | 15K | — | $0 |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 310K | — | — |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 93K | — | — |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 222K | — | — |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 21K | — | — |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 1.2M | — | — |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 29K | — | — |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 78K | — | — |
| Dec 18, 2023 | Baker Bros. Advisors LP | Director | Grant(A) | 973K | — | — |
| Oct 5, 2023 | Baker Bros. Advisors (GP) LLC | Director, 10% Owner | Option exercise(X) | 57K | — | — |
| Oct 5, 2023 | Baker Bros. Advisors (GP) LLC | Director, 10% Owner | Option exercise(X) | 536K | — | — |
| Oct 5, 2023 | Baker Bros. Advisors (GP) LLC | Director, 10% Owner | Option exercise(X) | 57K | — | $0 |
| Oct 5, 2023 | Baker Bros. Advisors (GP) LLC | Director, 10% Owner | Option exercise(X) | 536K | — | $0 |
| Aug 17, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 5K | $0.69 | $3K |
| Aug 17, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 8K | $0.69 | $5K |
| Aug 17, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 93K | $0.69 | $64K |
| Aug 17, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 61K | $0.69 | $42K |
| Aug 16, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 366 | $0.68 | $249 |
| Aug 16, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 208K | $0.68 | $141K |
| Aug 16, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 17K | $0.68 | $12K |
| Aug 16, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 4K | $0.68 | $3K |
| Aug 15, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 144K | $0.63 | $90K |
| Aug 15, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 358 | $0.67 | $240 |
| Aug 15, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 1.7M | $0.63 | $1.1M |
| Aug 15, 2023 | Baker Brothers Life Sciences LP | Director, 10% Owner | Buy(P) | 4K | $0.67 | $3K |
| Aug 11, 2023 | Smith Sean Michael | Interim CFO, Prin Acct Off | Sell(S) | 1K | $0.62 | $820 |
| Aug 10, 2023 | Smith Sean Michael | Interim CFO, Prin Acct Off | Option exercise(M) | 5K | — | $0 |
| Aug 10, 2023 | Smith Sean Michael | Interim CFO, Prin Acct Off | Option exercise(M) | 5K | — | $0 |
| Jun 8, 2023 | Baker Brothers Life Sciences LP | Director | Grant(A) | 25K | — | $0 |
| Jun 8, 2023 | Baker Brothers Life Sciences LP | Director | Grant(A) | 25K | — | $0 |
| Jun 8, 2023 | Simpson Todd E | Director | Grant(A) | 25K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Neurogene Inc., SEC CIK 0001404644. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under NLTX and shows every filing by that issuer (also filed as NGNE, AQXP). Earlier filings under the same symbol by another issuer are left out.
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-14. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for NLTX